Intercept Pharmaceuticals (NASDAQ:ICPT) had its price objective lowered by Stifel Nicolaus from $100.00 to $51.00 in a research report released on Monday, The Fly reports. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company’s stock.
Several other equities research analysts have also issued reports on ICPT. Goldman Sachs Group lowered shares of Intercept Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for the stock from $150.00 to $60.00 in a report on Monday. Needham & Company LLC restated a buy rating and issued a $150.00 target price on shares of Intercept Pharmaceuticals in a report on Monday, May 11th. Canaccord Genuity lowered shares of Intercept Pharmaceuticals from a buy rating to a hold rating and set a $58.00 target price for the company. in a report on Monday. Bank of America began coverage on shares of Intercept Pharmaceuticals in a report on Thursday, March 5th. They issued a neutral rating and a $111.00 target price for the company. Finally, Citigroup lowered shares of Intercept Pharmaceuticals from a buy rating to a neutral rating and set a $110.00 target price for the company. in a report on Tuesday, May 12th. Eighteen investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $74.13.
ICPT stock opened at $47.09 on Monday. Intercept Pharmaceuticals has a 52 week low of $44.50 and a 52 week high of $125.00. The company has a quick ratio of 4.19, a current ratio of 4.19 and a debt-to-equity ratio of 10.32. The company has a fifty day simple moving average of $77.14 and a two-hundred day simple moving average of $87.38. The firm has a market capitalization of $1.51 billion, a P/E ratio of -4.39 and a beta of 1.79.
In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the transaction, the director now owns 19,433 shares of the company’s stock, valued at approximately $1,644,031.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 595,817 shares of company stock worth $50,405,516 in the last three months. Insiders own 23.70% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ICPT. Norges Bank purchased a new position in Intercept Pharmaceuticals during the 4th quarter valued at about $37,422,000. Sarissa Capital Management LP lifted its stake in Intercept Pharmaceuticals by 34.3% during the 1st quarter. Sarissa Capital Management LP now owns 1,155,000 shares of the biopharmaceutical company’s stock valued at $72,718,000 after acquiring an additional 295,000 shares during the period. Macquarie Group Ltd. lifted its stake in Intercept Pharmaceuticals by 50.5% during the 4th quarter. Macquarie Group Ltd. now owns 545,414 shares of the biopharmaceutical company’s stock valued at $67,588,000 after acquiring an additional 183,072 shares during the period. Two Sigma Advisers LP lifted its stake in Intercept Pharmaceuticals by 37.5% during the 1st quarter. Two Sigma Advisers LP now owns 539,600 shares of the biopharmaceutical company’s stock valued at $33,973,000 after acquiring an additional 147,200 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Intercept Pharmaceuticals during the 4th quarter valued at approximately $11,425,000. 76.46% of the stock is currently owned by institutional investors and hedge funds.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.